ELK1 and prostate cancer: With the recent attention the MAPK-Elk1 axis has attracted and the evidence supporting STAT3 and cJun as potential therapeutic targets, we propose the three transcription factors as molecules of a significant role in the emergence of Bortezomib resistance, the targeting of which could truly improve the management of prostate cancer cases by expanding our drug repertoire and disease understanding.